Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma

Head and Neck

Volumn 25, Issue 6, 2003, Pages 457-463

  Kienstra, Matthew A ^a   Neel, H Bryan ^b   Strome, Scott E ^b   Roche, Patrick ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

MAGE 1; MAGE 3; NY ESO 1; Squamous cell carcinoma; Tumor antigens

Indexed keywords

MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 0038274027     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10223     Document Type: Article

References (15)

1. Chen Y-T, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918.
2. Van den Eynde B, Brichard VG. New tumor antigens recognized by T cells. Current Opin Immunol 1995;7:674-681.
3. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1196;183:725-729.
4. Stockert E, Jaeger E, Chen C-T, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354.
5. Jager E, Chen Y-T, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.
6. Old LJ, Chen Y-T. New paths in human cancer serology. J Exp Med 1998;187:1163-1167.
7. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
8. Gaugler B, van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
9. Jager E, Jager D, Knuth A. Peptide vaccination in clinical oncology. Onkologie 2000;23:410-415.
10. Eura M, Ogi K, Chikamatsu K, et al. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 1995;64:304-308.
11. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97:12198-12203.
12. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-860.
13. Fischer C, Gudat F, Stulz P et al. High expression of MAGE-3 protein in squamous-cell lung carcinoma. Int J Cancer 1997;71:1119-1121.
14. Jungbluth AA, Stockert E, Chen YT, et al. Monoclonal antibody MA454 reveals a heterogenous expression pattern of MAGE-1 antigen in formalin-fixed paraffin-embedded lung tumors. Br J Cancer 2000;83:493-497.
15. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:1635-1644.